Summit Trail Advisors LLC Has $302,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Summit Trail Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,285 shares of the biopharmaceutical company’s stock after buying an additional 151 shares during the quarter. Summit Trail Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $302,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. SYM FINANCIAL Corp boosted its holdings in Alnylam Pharmaceuticals by 6.2% during the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 55 shares during the last quarter. Lindbrook Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 57 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Alnylam Pharmaceuticals by 0.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock valued at $1,532,000 after acquiring an additional 58 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company’s stock valued at $624,000 after acquiring an additional 63 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 1.1 %

Shares of Alnylam Pharmaceuticals stock opened at $265.96 on Thursday. The stock has a market cap of $34.30 billion, a P/E ratio of -101.51 and a beta of 0.35. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business’s 50 day moving average is $253.77 and its 200-day moving average is $262.99.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday. Finally, Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.